GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (FRA:BIO) » Definitions » EV-to-EBITDA

Biotest AG (FRA:BIO) EV-to-EBITDA : 7.97 (As of May. 24, 2024)


View and export this data going back to 1987. Start your Free Trial

What is Biotest AG EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biotest AG's enterprise value is €1,864.8 Mil. Biotest AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €234.1 Mil. Therefore, Biotest AG's EV-to-EBITDA for today is 7.97.

The historical rank and industry rank for Biotest AG's EV-to-EBITDA or its related term are showing as below:

FRA:BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2300.98   Med: 12.79   Max: 620.58
Current: 7.97

During the past 13 years, the highest EV-to-EBITDA of Biotest AG was 620.58. The lowest was -2300.98. And the median was 12.79.

FRA:BIO's EV-to-EBITDA is ranked better than
54.93% of 446 companies
in the Biotechnology industry
Industry Median: 10.33 vs FRA:BIO: 7.97

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Biotest AG's stock price is €40.60. Biotest AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €5.156. Therefore, Biotest AG's PE Ratio for today is 7.87.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biotest AG EV-to-EBITDA Historical Data

The historical data trend for Biotest AG's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG EV-to-EBITDA Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.37 109.17 -113.03 86.29 11.97

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -99.68 91.82 10.31 11.97 6.75

Competitive Comparison of Biotest AG's EV-to-EBITDA

For the Biotechnology subindustry, Biotest AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biotest AG's EV-to-EBITDA falls into.



Biotest AG EV-to-EBITDA Calculation

Biotest AG's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1864.772/234.1
=7.97

Biotest AG's current Enterprise Value is €1,864.8 Mil.
Biotest AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €234.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotest AG  (FRA:BIO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biotest AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=40.60/5.156
=7.87

Biotest AG's share price for today is €40.60.
Biotest AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.156.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biotest AG EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biotest AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (FRA:BIO) Business Description

Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (FRA:BIO) Headlines